Apyx Medical Stock Forecast, Price & News

Apyx Medical (NASDAQ:APYX) Frequently Asked Questions

Is Apyx Medical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apyx Medical in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Apyx Medical stock.
View analyst ratings for Apyx Medical or view top-rated stocks.

How has Apyx Medical's stock been impacted by Coronavirus?

Apyx Medical's stock was trading at $5.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APYX stock has increased by 150.6% and is now trading at $12.68.
View which stocks have been most impacted by COVID-19.

When is Apyx Medical's next earnings date?

Apyx Medical is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for Apyx Medical.

How were Apyx Medical's earnings last quarter?

Apyx Medical Co. (NASDAQ:APYX) released its quarterly earnings results on Thursday, November, 11th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.03. Apyx Medical had a negative trailing twelve-month return on equity of 24.87% and a negative net margin of 34.05%. During the same quarter last year, the business posted ($0.13) earnings per share.
View Apyx Medical's earnings history.

What guidance has Apyx Medical issued on next quarter's earnings?

Apyx Medical issued an update on its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $44 million-$45 million, compared to the consensus revenue estimate of $41.74 million.

What price target have analysts set for APYX?

3 brokers have issued 1-year price objectives for Apyx Medical's stock. Their forecasts range from $14.00 to $20.00. On average, they expect Apyx Medical's stock price to reach $17.00 in the next year. This suggests a possible upside of 34.1% from the stock's current price.
View analysts' price targets for Apyx Medical or view top-rated stocks among Wall Street analysts.

Who are Apyx Medical's key executives?

Apyx Medical's management team includes the following people:

• Charles D. Goodwin, President, Chief Executive Officer & Director
• Tara H. Semb, Chief Financial Officer, Secretary & Treasurer
• Shawn D. Roman, Director-Research & Development
• Kari Larson, Senior Director-Clinical Affairs
• Todd Hornsby, Executive Vice President

Who are some of Apyx Medical's key competitors?

Some companies that are related to Apyx Medical include Paragon 28 (FNA), Silk Road Medical (SILK), Inovio Pharmaceuticals (INO), Procept BioRobotics (PRCT), Atrion (ATRI), Cerus (CERS), OrthoPediatrics (KIDS), Alphatec (ATEC), Pulmonx (LUNG), AngioDynamics (ANGO), LeMaitre Vascular (LMAT), Sight Sciences (SGHT), Bioventus (BVS), Treace Medical Concepts (TMCI) and Intersect ENT (XENT).
View all of APYX's competitors.

What other stocks do shareholders of Apyx Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apyx Medical investors own include Main Street Capital (MAIN), Johnson & Johnson (JNJ), ONEOK (OKE), Occidental Petroleum (OXY), Procter & Gamble (PG), STORE Capital (STOR), Wells Fargo & Company (WFC), Boeing (BA), Bank of America (BAC) and Delta Air Lines (DAL).

What is Apyx Medical's stock symbol?

Apyx Medical trades on the NASDAQ under the ticker symbol "APYX."

Who are Apyx Medical's major shareholders?

Apyx Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include RTW Investments LP (9.90%), Cowen AND Company LLC (5.47%), Pura Vida Investments LLC (2.50%), Taylor Frigon Capital Management LLC (1.67%), Dimensional Fund Advisors LP (1.53%) and Geode Capital Management LLC (1.44%).
View institutional ownership trends for Apyx Medical.

Which institutional investors are selling Apyx Medical stock?

APYX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Pura Vida Investments LLC, Renaissance Technologies LLC, California State Teachers Retirement System, Goldman Sachs Group Inc., Jane Street Group LLC, Citadel Advisors LLC, and Morgan Stanley.
View insider buying and selling activity for Apyx Medical or view top insider-selling stocks.

Which institutional investors are buying Apyx Medical stock?

APYX stock was bought by a variety of institutional investors in the last quarter, including Cowen AND Company LLC, EAM Investors LLC, Greenwood Capital Associates LLC, Franklin Resources Inc., Dimensional Fund Advisors LP, Calamos Advisors LLC, Russell Investments Group Ltd., and SG Americas Securities LLC.
View insider buying and selling activity for Apyx Medical or or view top insider-buying stocks.

How do I buy shares of Apyx Medical?

Shares of APYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apyx Medical's stock price today?

One share of APYX stock can currently be purchased for approximately $12.68.

How much money does Apyx Medical make?

Apyx Medical has a market capitalization of $435.43 million and generates $27.71 million in revenue each year. The company earns $-11.90 million in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does Apyx Medical have?

Apyx Medical employs 266 workers across the globe.

What is Apyx Medical's official website?

The official website for Apyx Medical is www.apyxmedical.com.

Where are Apyx Medical's headquarters?

Apyx Medical is headquartered at 5115 Ulmerton Road, Clearwater FL, 33760.

How can I contact Apyx Medical?

Apyx Medical's mailing address is 5115 Ulmerton Road, Clearwater FL, 33760. The company can be reached via phone at (727) 384-2323, via email at [email protected], or via fax at 800-323-1640.